Early treatment with the antiviral drug remdesivir is shown to reduce viral load and prevent lung disease in macaques infected with SARS-CoV-2, reports a study published in Nature today. The findings support the early use of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.
Remdesivir has broad antiviral activity and has been shown to be effective against infections with SARS-CoV and MERS-CoV in animal models. The drug is being tested in human clinical trials for the treatment of COVID-19.
Emmie de Wit and colleagues investigated the effects of remdesivir treatment in rhesus macaques, a recently established model of SARS-CoV-2 infection. Two sets of six macaques were inoculated with SARS-CoV-2; one group was treated with remdesivir 12 hours later (close to the peak of virus replication in the lungs) and these macaques received treatment every 24 hours until six days after inoculation. In contrast to the control group, macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs. Viral loads in the lower respiratory tract were also reduced in the treated animals; viral levels were around 100 times lower in the lower-respiratory tract of remdesivir-treated macaques 12 hours after the first dose. Infectious virus could no longer be detected in the treatment group three days after initial infection, but was still detectable in four out of six control animals. Despite this virus reduction in the lower respiratory tract, no reduction in virus shedding was observed, which indicates that clinical improvement may not equate to a lack of infectiousness.
Dosing of remdesivir in the rhesus macaques is equivalent to that used in humans, the authors note. They caution that it is difficult to directly translate the timing of treatment used in corresponding disease stages in humans, because rhesus macaques normally develop only mild disease. However, their results indicate that remdesivir treatment of COVID-19 should be initiated as early as possible to achieve the maximum treatment effect.
Genetics: Correcting for genetic associations between alcohol and diseaseNature Communications
Biomedical engineering: Tiny device goes with the (blood) flowNature Communications